Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients | Zendy

Laurence Bocket | Zendy; Gilles Peytavin | Zendy; Enag Kazali Alidjinou | Zendy; F. Ajana | Zendy; P. Choisy | Zendy; Minh Patrick Lê | Zendy; C. Charpentier | Zendy; Diane Descamps | Zendy; Yazdan Yazdanpanah | Zendy; Christine Katlama | Zendy; Anne Simon | Zendy; Vincent Cálvez | Zendy; AnneGeneviève Marcelin | Zendy; Cathia Soulié | Zendy

Open Access

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients

Author(s) -

Laurence Bocket,

Gilles Peytavin,

Enag Kazali Alidjinou,

F. Ajana,

P. Choisy,

Minh Patrick Lê,

C. Charpentier,

Diane Descamps,

Yazdan Yazdanpanah,

Christine Katlama,

Anne Simon,

Vincent Cálvez,

AnneGeneviève Marcelin,

Cathia Soulié

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw167

Subject(s) - maraviroc , raltegravir , regimen , medicine , viral load , ccr5 receptor antagonist , univariate analysis , gastroenterology , tissue tropism , surgery , immunology , multivariate analysis , human immunodeficiency virus (hiv) , tropism , antiretroviral therapy , virus , receptor , chemokine , chemokine receptor

There are few data on clinical and virological factors associated with maraviroc virological response (VR) in clinical practice. This study aimed to identify factors associated with VR in 94 treatment-experienced, but CCR5 inhibitor-naive, HIV-1 patients switched to maraviroc-containing regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research